176 related articles for article (PubMed ID: 27579542)
1. METFORMIN: NONGLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS.
Anabtawi A; Miles JM
Endocr Pract; 2016 Aug; 22(8):999-1007. PubMed ID: 27579542
[TBL] [Abstract][Full Text] [Related]
2. Use of metformin in diseases of aging.
Miles JM; Rule AD; Borlaug BA
Curr Diab Rep; 2014 Jun; 14(6):490. PubMed ID: 24752835
[TBL] [Abstract][Full Text] [Related]
3. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
Charytan DM; Solomon SD; Ivanovich P; Remuzzi G; Cooper ME; McGill JB; Parving HH; Parfrey P; Singh AK; Burdmann EA; Levey AS; Eckardt KU; McMurray JJV; Weinrauch LA; Liu J; Claggett B; Lewis EF; Pfeffer MA
Diabetes Obes Metab; 2019 May; 21(5):1199-1208. PubMed ID: 30672083
[TBL] [Abstract][Full Text] [Related]
4. Metformin: time to review its role and safety in chronic kidney disease.
Tanner C; Wang G; Liu N; Andrikopoulos S; Zajac JD; Ekinci EI
Med J Aust; 2019 Jul; 211(1):37-42. PubMed ID: 31187887
[TBL] [Abstract][Full Text] [Related]
5. Metformin in chronic kidney disease: time for a rethink.
Heaf J
Perit Dial Int; 2014 Jun; 34(4):353-7. PubMed ID: 24711640
[TBL] [Abstract][Full Text] [Related]
6. Appropriateness of metformin prescription for type 2 diabetes mellitus patients with chronic kidney disease (Stages 3-5).
Ramachandran M; Loi B; Mat Ariff N; Ng OC; Zahari Sham SY; Thambiah SC; Samsudin IN
Malays J Pathol; 2020 Apr; 42(1):71-76. PubMed ID: 32342933
[TBL] [Abstract][Full Text] [Related]
7. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.
Han Y; Xie H; Liu Y; Gao P; Yang X; Shen Z
Cardiovasc Diabetol; 2019 Jul; 18(1):96. PubMed ID: 31362743
[TBL] [Abstract][Full Text] [Related]
8. Metformin: New Preparations and Nonglycemic Benefits.
Fujita Y; Inagaki N
Curr Diab Rep; 2017 Jan; 17(1):5. PubMed ID: 28116648
[TBL] [Abstract][Full Text] [Related]
9. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
Min T; Davies GI; Rice S; Chess J; Stephens JW
Diabetes Metab Syndr; 2018; 12(2):123-127. PubMed ID: 29239764
[TBL] [Abstract][Full Text] [Related]
10. Managing type 2 diabetes: going beyond glycemic control.
Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
[TBL] [Abstract][Full Text] [Related]
11. Metformin as first choice in oral diabetes treatment: the UKPDS experience.
Holman R
Journ Annu Diabetol Hotel Dieu; 2007; ():13-20. PubMed ID: 18613325
[TBL] [Abstract][Full Text] [Related]
12. Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3-5: is it significant?
Prabhu RA; Mareddy AS; Nagaraju SP; Rangaswamy D; Guddattu V
Int Urol Nephrol; 2019 Jul; 51(7):1229-1230. PubMed ID: 30963454
[TBL] [Abstract][Full Text] [Related]
13. Renal function markers and metformin eligibility.
Tavares Bello C; Castro Fonseca R; Sousa Santos F; Sequeira Duarte J; Azinheira J; Vasconcelos C
Minerva Endocrinol; 2018 Sep; 43(3):246-252. PubMed ID: 28565889
[TBL] [Abstract][Full Text] [Related]
14. Metformin use in patients with type 2 diabetes mellitus and chronic kidney disease: An evidence-based review.
Tan FCJH; Ang SB; Bee YM
Ann Acad Med Singap; 2021 Feb; 50(2):159-170. PubMed ID: 33733259
[TBL] [Abstract][Full Text] [Related]
15. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
16. A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.
Whitlock RH; Hougen I; Komenda P; Rigatto C; Clemens KK; Tangri N
Mayo Clin Proc; 2020 Jan; 95(1):90-100. PubMed ID: 31902433
[TBL] [Abstract][Full Text] [Related]
17. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
18. Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease.
Marcum ZA; Forsberg CW; Moore KP; de Boer IH; Smith NL; Boyko EJ; Floyd JS
J Gen Intern Med; 2018 Feb; 33(2):155-165. PubMed ID: 29181788
[TBL] [Abstract][Full Text] [Related]
19. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
20. Assessment of serum creatinine and kidney function among incident metformin users.
Schorr M; Hemmelgarn BR; Tonelli M; Soo A; Manns BJ; Bresee LC;
Can J Diabetes; 2013 Aug; 37(4):226-230. PubMed ID: 24070885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
